Advanced neuroimaging assessment of neurodegenerative dementia syndromes: A framework for comprehensive multimodal FDG-PET, MR-perfusion, and MR-diffusion analysis.

BACKGROUND

The reference for imaging in neurodegenerative dementia syndromes (NDS) is [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET). Advanced multimodal magnetic resonance imaging (MRI) may complement PET-derived measures for differential diagnostics.

OBJECTIVES

The aim of the present study was to evaluate a new methodological approach integrating metabolic, perfusion, and microstructural parameters from simultaneous FDG-PET/MRI to reveal different imaging signatures for different NDS subtypes.

MATERIALS AND

METHODS

66 patients with NDS (Alzheimer's disease: 28; behavioral frontotemporal dementia: 10; semantic variant primary progressive aphasia (PPA): 8; non-fluent variant PPA: 11; logopenic variant PPA: 9) and 10 subjects with subjective cognitive deficits (SCD) underwent combined FDG-PET/MRI with pseudo-continuous arterial spin labeling (pCASL) and diffusion tensor imaging (DTI). Standardized uptake values (SUV), cerebral blood flow (CBF), and fractional anisotropy (FA) were used to separate a respective NDS subgroup from all other NDS subgroups and from SCD based on a support vector machine (SVM) applied on region of interest (ROI)-based parameters.

RESULTS

White matter alterations directly adjacent to the regions of alterations in SUV and CBF were identified. The SVM analysis on ROI-based parameters reached accuracies between 81% and 94% for separating an NDS subgroup from all other NDS subgroups and from SCD.

CONCLUSIONS

Multimodal neuroimaging by combination of FDG-PET and MRI shows potential to further advance the diagnostic spectrum in NDS. Since particularly early diagnosis of NDS remains key for effective treatment and management of patients with NDS, the present framework appears promising to be developed further until it aligns and integrates with clinical routine.